- Therapy may cause cardiac adverse reactions including heart failure and ischemia. Suspend therapy if cardiac complications occur
- Carfilzomib should be discontinued if pulmonary hypertension occurs
- Therapy may cause pulmonary complications such as dyspnea. Monitor and manage dyspnea immediately; interrupt carfilzomib until symptoms have resolved or returned to baseline
- Before administering carfilzomib, pre-medication with dexamethasone should be given to avoid infusion reaction
- Tumor lysis syndrome (TLS) may occur follwing carfilzomib administration. Prior to receiving carfilzomib, appropriate hydration of the patient should be ensured
- Carfilzomib may induce thrombocytopenia; therefore, platelet counts should be monitored periodically to reduce the instance of thrombocytopenia
- Instances of hepatic toxicity resulting in hepatic failure have occured during therapy. Monitor liver enzymes and suspend therapy if liver toxicity is suspected
- Carfilzomib administration in pregnancy may cause fetal harm. Avoid therapy in females of reproductive potential
Cautions: Use cautiously in
- Class III to IV CHF
- MI within 6 months
- Dehydration
- History of herpes zoster
- Cardiac conduction abnormalities
- High tumor burden
Pregnancy Category:D
Breastfeeding: Safety unknown. Due to the potential for serious adverse reactions in nursing infants, manufacturer advises to discontinue nursing or to discontinue the drug.
1 hr
